Urine-Based Molecular Testing Service

Contract for a Urine-Based Molecular Testing Service --- Extracted from documents --- Urine-Based Molecular Testing Service University Hospitals of North Midlands NHS Trust F14: Notice for changes or additional information Notice identifier: 2026/S 000-086052 Procurement identifier (OCID): ocds-h6vhtk-06df03 Published 10 September 2026, 3:51pm Watch this notice Contents Open all one. Contracting authority/entity I. Contracting authority/entity Press escape key to exit two. Object II. Object six. Complementary information VI. Complementary information seven. Changes VII. Changes Download OCDS release OCDS record Share this notice Twitter LinkedIn Email Copy link Print this notice Report concerns about this procurement Section one: Contracting authority/entity Section I: Contracting authority/entity one.1) Name and addresses I.1) Name and addresses University Hospitals of North Midlands NHS Trust Royal Stoke University Hospial, Newcastle Road Stoke on Trent ST4 6QG Contact Lisa Buckley Email lisa.buckley@uhnm.nhs.uk Country United Kingdom Region code UKG - West Midlands (England) Internet address(es) Main address https://www.uhnm.nhs.uk/ Buyer's address https://www.uhnm.nhs.uk/ Section two: Object Section II: Object two.1) Scope of the procurement II.1) Scope of the procurement two.1.1) Title II.1.1) Title Urine-Based Molecular Testing Service Reference number MED9962 two.1.2) Main CPV code II.1.2) Main CPV code 85100000 - Health services two.1.3) Type of contract II.1.3) Type of contract Services two.1.4) Short description II.1.4) Short description Contract for a Urine-Based Molecular Testing Service Section six. Complementary information Section VI. Complementary information six.6) Original notice reference VI.6) Original notice reference Notice number: 2026/S 000-075257 Section seven. Changes Section VII. Changes seven.1.2) Text to be corrected in the original notice VII.1.2) Text to be corrected in the original notice Section number II.2.4.1. Instead of Text UHNM requires a urine-based molecular testing service from 1 October 2026 to 31 March 2027 to support triage of eligible patients on the non-visible haematuria pathway.The service must provide a safe, non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort, while maintaining clinical oversight, safety-netting and rapid escalation for patients with positive or high-risk results.Scope: The service will apply to patients referred to the UHNM non-visible haematuria pathway who meet locally agreed eligibility criteria. The provider must support home urine sample collection where required, sample return logistics, laboratory analysis, secure reporting of results, and operational data provision. Visible haematuria pathways, confirmed bladder cancer management, and patients requiring cystoscopy for other clinical indications are excluded from scope unless otherwise agreed.Core provider responsibilities: The supplier must provide clear patient instructions, sample k...